Susan A Ridge

TL;DR: The studies show that the CB1 receptor has a role in the regulation of bone mass and ovariectomy-induced bone loss and that CB1- and CB2-selective cannabinoid receptor antagonists are a new class of osteoclast inhibitors that may be of value in the treatment of osteoporosis and other bone diseases.

TL;DR: The five mutations analysed in this study are insufficient for identification of patients at risk for 5FU toxicity or thymine uraciluria, and identification of further molecular alterations is required to facilitate the use of DPD analysis in genetic diagnosis and cancer therapeutics.

TL;DR: DPD mRNA expression was higher in normal liver than normal colonic mucosa, and a significant relationship was observed between DPD mRNA and catalytic activity, which suggests that DPD can be regulated at the levels of both transcription and translation.

TL;DR: Two new mutations at codons 534 and 543 in the DPD cDNA of a patient with low enzyme activity are identified and the DNA from 75 colorectal cancer patients are screened for these mutations and the previously reported splice site mutation.

TL;DR: A novel class of biphenylcarboxylic acid derivatives are described that inhibit osteoclastic bone resorption in vitro by promoting osteoclast apoptosis and that prevent ovariectomy‐induced bone loss in vivo.